Overview Dividends

(AXSM) Axsome Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US05464T1043

Antidepressant, Wake-Promoting, Migraine, Alzheimer, Narcolepsy

EPS (Earnings per Share)

EPS (Earnings per Share) of AXSM over the last years for every Quarter: "2020-09": -0.58, "2020-12": -0.78, "2021-03": -0.78, "2021-06": -0.86, "2021-09": -0.93, "2021-12": -0.9, "2022-03": -1.03, "2022-06": -1.06, "2022-09": -1.07, "2022-12": -1.41, "2023-03": -0.26, "2023-06": -1.54, "2023-09": -1.32, "2023-12": -2.08, "2024-03": -1.44, "2024-06": -1.67, "2024-09": -1.3419, "2024-12": -1.54, "2025-03": -1.2157, "2025-06": -0.97, "2025-09": -0.94,
EPS CAGR: 18.15%
EPS Trend: -1.5%
Last SUE: -0.33σ
Qual. Beats: 0

Revenue

Revenue of AXSM over the last years for every Quarter: 2020-09: 0, 2020-12: 0, 2021-03: 0, 2021-06: 0, 2021-09: 0, 2021-12: 0, 2022-03: 0, 2022-06: 8.82, 2022-09: 16.846, 2022-12: 24.371528, 2023-03: 94.576, 2023-06: 46.7, 2023-09: 57.794, 2023-12: 71.53, 2024-03: 74.999, 2024-06: 87.166, 2024-09: 104.762, 2024-12: 118.766, 2025-03: 121.463, 2025-06: 150.042, 2025-09: 170.992,
Revenue CAGR: 103.08%
Revenue Trend: 86.7%
Last SUE: 2.02σ
Qual. Beats: 2
Risk via 10d forecast
Volatility 41.9%
Value at Risk 5%th 63.4%
Relative Tail Risk -7.95%
Reward TTM
Sharpe Ratio 1.07
Alpha 41.35
Character TTM
Hurst Exponent 0.622
Beta 0.697
Beta Downside 0.888
Drawdowns 3y
Max DD 36.45%
Mean DD 14.76%
Median DD 14.94%

Description: AXSM Axsome Therapeutics November 05, 2025

Axsome Therapeutics (NASDAQ: AXSM) is a U.S.-based biopharma that targets central nervous system (CNS) disorders. Its commercial lineup includes Auvelity (dextromethorphan-bupropion) for major depressive disorder, Sunosi (solriamfetol) for excessive daytime sleepiness in narcolepsy or obstructive sleep apnea, and Symbravo (AXS-07), a rapid-onset migraine therapy that combines meloxicam and rizatriptan.

The pipeline features several late-stage candidates: AXS-05 (dextromethorphan-bupropion) has finished Phase III for Alzheimer’s disease agitation and Phase II for smoking cessation; AXS-12 (reboxetine) completed Phase III for narcolepsy; AXS-14 (esreboxetine) wrapped Phase III for fibromyalgia; and Solriamfetol is in Phase III trials for ADHD, major depression, binge-eating disorder, and shift-work sleepiness. Axsome also maintains a research collaboration with Duke University to evaluate AXS-05 in smoking cessation.

As of the latest quarter (Q2 2024), Axsome reported $68 million in total revenue, driven primarily by Sunosi and Auvelity, and held $550 million of cash and marketable securities, giving it roughly 18 months of runway at current burn rates. The CNS therapeutics market is expanding at a 6-7 % CAGR, buoyed by aging demographics and unmet needs in depression and sleep disorders-trends that underpin Axsome’s growth thesis. For a deeper dive into the company’s valuation dynamics, a quick look at ValueRay’s analyst toolkit can help surface the most material assumptions.

AXSM Stock Overview

Market Cap in USD 7,534m
Sub-Industry Pharmaceuticals
IPO / Inception 2015-11-19
Return 12m vs S&P 500 34.9%
Analyst Rating 4.74 of 5

AXSM Dividends

Currently no dividends paid

AXSM Growth Ratios

Metric Value
CAGR 3y 27.94%
CAGR/Max DD Calmar Ratio 0.77
CAGR/Mean DD Pain Ratio 1.89
Current Volume 359.5k
Average Volume 531.8k

Piotroski VR‑10 (Strict, 0-10) 3.0

Net Income (-229.5m TTM) > 0 and > 6% of Revenue (6% = 33.7m TTM)
FCFTA -0.15 (>2.0%) and ΔFCFTA 8.52pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 36.53% (prev 83.59%; Δ -47.06pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.15 (>3.0%) and CFO -101.0m > Net Income -229.5m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 1.57 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (50.0m) change vs 12m ago 3.91% (target <= -2.0% for YES)
Gross Margin 91.86% (prev 91.09%; Δ 0.78pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 91.21% (prev 60.28%; Δ 30.93pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -29.04 (EBITDA TTM -212.3m / Interest Expense TTM 7.59m) >= 6 (WARN >= 3)

Altman Z'' -8.87

(A) 0.31 = (Total Current Assets 565.3m - Total Current Liabilities 360.3m) / Total Assets 669.2m
(B) -1.91 = Retained Earnings (Balance) -1.28b / Total Assets 669.2m
warn (B) unusual magnitude: -1.91 — check mapping/units
(C) -0.36 = EBIT TTM -220.5m / Avg Total Assets 615.4m
(D) -2.15 = Book Value of Equity -1.28b / Total Liabilities 595.5m
Total Rating: -8.87 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 33.58

1. Piotroski 3.0pt
2. FCF Yield -1.36%
3. FCF Margin -18.00%
4. Debt/Equity 2.96
5. Debt/Ebitda 0.50
6. ROIC - WACC (= -97.07)%
7. RoE -357.2%
8. Rev. Trend 86.67%
9. EPS Trend -1.48%

What is the price of AXSM shares?

As of November 26, 2025, the stock is trading at USD 150.36 with a total of 359,541 shares traded.
Over the past week, the price has changed by +1.95%, over one month by +11.64%, over three months by +29.28% and over the past year by +54.22%.

Is AXSM a buy, sell or hold?

Axsome Therapeutics has received a consensus analysts rating of 4.74. Therefore, it is recommended to buy AXSM.
  • Strong Buy: 14
  • Buy: 5
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the AXSM price?

Issuer Target Up/Down from current
Wallstreet Target Price 179.7 19.5%
Analysts Target Price 179.7 19.5%
ValueRay Target Price 186.6 24.1%

AXSM Fundamental Data Overview November 24, 2025

Market Cap USD = 7.53b (7.53b USD * 1.0 USD.USD)
P/E Forward = 625.0
P/S = 13.4227
P/B = 102.1833
Beta = 0.48
Revenue TTM = 561.3m USD
EBIT TTM = -220.5m USD
EBITDA TTM = -212.3m USD
Long Term Debt = 117.6m USD (from longTermDebt, last quarter)
Short Term Debt = 73.2m USD (from shortTermDebt, last quarter)
Debt = 218.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -106.7m USD (from netDebt column, last quarter)
Enterprise Value = 7.43b USD (7.53b + Debt 218.6m - CCE 325.3m)
Interest Coverage Ratio = -29.04 (Ebit TTM -220.5m / Interest Expense TTM 7.59m)
FCF Yield = -1.36% (FCF TTM -101.0m / Enterprise Value 7.43b)
FCF Margin = -18.00% (FCF TTM -101.0m / Revenue TTM 561.3m)
Net Margin = -40.89% (Net Income TTM -229.5m / Revenue TTM 561.3m)
Gross Margin = 91.86% ((Revenue TTM 561.3m - Cost of Revenue TTM 45.7m) / Revenue TTM)
Gross Margin QoQ = 93.03% (prev 91.04%)
Tobins Q-Ratio = 11.10 (Enterprise Value 7.43b / Total Assets 669.2m)
Interest Expense / Debt = 0.51% (Interest Expense 1.12m / Debt 218.6m)
Taxrate = -0.0% (0.0 / -47.2m)
NOPAT = -220.5m (EBIT -220.5m * (1 - -0.00%)) [loss with tax shield]
Current Ratio = 1.57 (Total Current Assets 565.3m / Total Current Liabilities 360.3m)
Debt / Equity = 2.96 (Debt 218.6m / totalStockholderEquity, last quarter 73.7m)
Debt / EBITDA = 0.50 (negative EBITDA) (Net Debt -106.7m / EBITDA -212.3m)
Debt / FCF = 1.06 (negative FCF - burning cash) (Net Debt -106.7m / FCF TTM -101.0m)
Total Stockholder Equity = 64.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -34.30% (Net Income -229.5m / Total Assets 669.2m)
RoE = -357.2% (Net Income TTM -229.5m / Total Stockholder Equity 64.3m)
RoCE = -121.2% (out of range, set to none) (EBIT -220.5m / Capital Employed (Equity 64.3m + L.T.Debt 117.6m))
RoIC = -88.72% (negative operating profit) (NOPAT -220.5m / Invested Capital 248.6m)
WACC = 8.35% (E(7.53b)/V(7.75b) * Re(8.58%) + D(218.6m)/V(7.75b) * Rd(0.51%) * (1-Tc(-0.0)))
Discount Rate = 8.58% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 2.80%
Fair Price DCF = unknown (Cash Flow -101.0m)
EPS Correlation: -1.48 | EPS CAGR: 18.15% | SUE: -0.33 | # QB: 0
Revenue Correlation: 86.67 | Revenue CAGR: 103.1% | SUE: 2.02 | # QB: 2

Additional Sources for AXSM Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle